-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on July 8 A few days ago, Tianjin Hongri Pharmaceutical's application for the listing of the 4 generic generic pramipexole hydrochloride tablets has entered the administrative approval stage
.
According to data from Meinenet, this product is the best-selling anti-Parkinson's disease drug in China's public medical institutions in 2020, and it ranks second in the competitive landscape of anti-Parkinson's drug products in urban physical pharmacies in China
.
.
According to data from Meinenet, this product is the best-selling anti-Parkinson's disease drug in China's public medical institutions in 2020, and it ranks second in the competitive landscape of anti-Parkinson's drug products in urban physical pharmacies in China
.
Source: official website of the State Drug Administration
Pramipexole is a dopamine receptor agonist that binds to the D2 subfamily of dopamine receptors with high selectivity and specificity, and has complete intrinsic activity.
It has a preferential affinity for the D3 receptor in it and can be clinically independent ( No levodopa) or combined with levodopa to treat the signs and symptoms of idiopathic Parkinson's disease
.
It has a preferential affinity for the D3 receptor in it and can be clinically independent ( No levodopa) or combined with levodopa to treat the signs and symptoms of idiopathic Parkinson's disease
.
In recent years, as the aging of the population has accelerated, the prevalence of Parkinson's disease has increased, and the market for related drugs has expanded
.
According to data from Meinenet, in 2020, the total market size of anti-Parkinson drugs in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeds 2.
5 billion yuan, year-on-year An increase of 14.
7%
.
.
According to data from Meinenet, in 2020, the total market size of anti-Parkinson drugs in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeds 2.
5 billion yuan, year-on-year An increase of 14.
7%
.
In the competitive landscape of terminal anti-Parkinson drug products in China's public medical institutions in 2020, pramipexole hydrochloride tablets ranked first with about 33% market share, and pramipexole hydrochloride sustained-release tablets ranked first with about 5% market share.
No.
7
.
No.
7
.
2020 China's urban physical pharmacies terminal anti-Parkinson drug TOP10 products
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In 2020, in the competitive landscape of terminal anti-Parkinson drug products in Chinese urban physical pharmacies, dopasserazine tablets ranked first with about 37% market share, and pramipexole hydrochloride tablets ranked second with about 26% market share
.
From the perspective of brand structure, domestic anti-Parkinson drugs are still dominated by multinational pharmaceutical companies
.
.
From the perspective of brand structure, domestic anti-Parkinson drugs are still dominated by multinational pharmaceutical companies
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Medical Network News on July 8 A few days ago, Tianjin Hongri Pharmaceutical's application for the listing of the 4 generic generic pramipexole hydrochloride tablets has entered the administrative approval stage
.
According to data from Meinenet, this product is the best-selling anti-Parkinson's disease drug in China's public medical institutions in 2020, and it ranks second in the competitive landscape of anti-Parkinson's drug products in urban physical pharmacies in China
.
.
According to data from Meinenet, this product is the best-selling anti-Parkinson's disease drug in China's public medical institutions in 2020, and it ranks second in the competitive landscape of anti-Parkinson's drug products in urban physical pharmacies in China
.
Source: official website of the State Drug Administration
Pramipexole is a dopamine receptor agonist that binds to the D2 subfamily of dopamine receptors with high selectivity and specificity, and has complete intrinsic activity.
It has a preferential affinity for the D3 receptor in it and can be clinically independent ( No levodopa) or combined with levodopa to treat the signs and symptoms of idiopathic Parkinson's disease
.
It has a preferential affinity for the D3 receptor in it and can be clinically independent ( No levodopa) or combined with levodopa to treat the signs and symptoms of idiopathic Parkinson's disease
.
In recent years, as the aging of the population has accelerated, the prevalence of Parkinson's disease has increased, and the market for related drugs has expanded
.
According to data from Meinenet, in 2020, the total market size of anti-Parkinson drugs in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeds 2.
5 billion yuan, year-on-year An increase of 14.
7%
.
.
According to data from Meinenet, in 2020, the total market size of anti-Parkinson drugs in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeds 2.
5 billion yuan, year-on-year An increase of 14.
7%
.
In the competitive landscape of terminal anti-Parkinson drug products in China's public medical institutions in 2020, pramipexole hydrochloride tablets ranked first with about 33% market share, and pramipexole hydrochloride sustained-release tablets ranked first with about 5% market share.
No.
7
.
No.
7
.
2020 China's urban physical pharmacies terminal anti-Parkinson drug TOP10 products
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In 2020, in the competitive landscape of terminal anti-Parkinson drug products in Chinese urban physical pharmacies, dopasserazine tablets ranked first with about 37% market share, and pramipexole hydrochloride tablets ranked second with about 26% market share
.
From the perspective of brand structure, domestic anti-Parkinson drugs are still dominated by multinational pharmaceutical companies
.
.
From the perspective of brand structure, domestic anti-Parkinson drugs are still dominated by multinational pharmaceutical companies
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Medical Network News on July 8 A few days ago, Tianjin Hongri Pharmaceutical's application for the listing of the 4 generic generic pramipexole hydrochloride tablets has entered the administrative approval stage
.
According to data from Meinenet, this product is the best-selling anti-Parkinson's disease drug in China's public medical institutions in 2020, and it ranks second in the competitive landscape of anti-Parkinson's drug products in urban physical pharmacies in China
.
.
According to data from Meinenet, this product is the best-selling anti-Parkinson's disease drug in China's public medical institutions in 2020, and it ranks second in the competitive landscape of anti-Parkinson's drug products in urban physical pharmacies in China
.
Source: official website of the State Drug Administration
Pramipexole is a dopamine receptor agonist that binds to the D2 subfamily of dopamine receptors with high selectivity and specificity, and has complete intrinsic activity.
It has a preferential affinity for the D3 receptor in it and can be clinically independent ( No levodopa) or combined with levodopa to treat the signs and symptoms of idiopathic Parkinson's disease
.
It has a preferential affinity for the D3 receptor in it and can be clinically independent ( No levodopa) or combined with levodopa to treat the signs and symptoms of idiopathic Parkinson's disease
.
In recent years, as the aging of the population has accelerated, the prevalence of Parkinson's disease has increased, and the market for related drugs has expanded
.
According to data from Meinenet, in 2020, the total market size of anti-Parkinson drugs in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeds 2.
5 billion yuan, year-on-year An increase of 14.
7%
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
According to data from Meinenet, in 2020, the total market size of anti-Parkinson drugs in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeds 2.
5 billion yuan, year-on-year An increase of 14.
7%
.
In the competitive landscape of terminal anti-Parkinson drug products in China's public medical institutions in 2020, pramipexole hydrochloride tablets ranked first with about 33% market share, and pramipexole hydrochloride sustained-release tablets ranked first with about 5% market share.
No.
7
.
No.
7
.
2020 China's urban physical pharmacies terminal anti-Parkinson drug TOP10 products
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In 2020, in the competitive landscape of terminal anti-Parkinson drug products in Chinese urban physical pharmacies, dopasserazine tablets ranked first with about 37% market share, and pramipexole hydrochloride tablets ranked second with about 26% market share
.
From the perspective of brand structure, domestic anti-Parkinson drugs are still dominated by multinational pharmaceutical companies
.
.
From the perspective of brand structure, domestic anti-Parkinson drugs are still dominated by multinational pharmaceutical companies
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
